Oncology Institute (TOI) Non-Current Deffered Revenue (2020 - 2021)
Oncology Institute (TOI) posted Non-Current Deffered Revenue of $6.3 million for Q3 2021, little changed quarter-over-quarter from $6.3 million in Q2 2021, and little changed year-on-year from $6.3 million in Q3 2020.
Oncology Institute (TOI) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Oncology Institute (TOI) has reported Non-Current Deffered Revenue for 2 consecutive years, with $6.3 million the latest figure, recorded in Q3 2021.
- Non-Current Deffered Revenue for Q3 2021 came in at $6.3 million, changed 0.0% year-over-year; the trailing twelve-month figure through Sep 2021 was $6.3 million (changed 0.0% YoY), and the FY2020 annual result was $6.3 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was $6.3 million for Q3 2021 at Oncology Institute, roughly flat from $6.3 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $6.3 million in Q1 2020 and troughed at $6.3 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | HCA Healthcare | 87.94 Bn | 90.32 Bn | 16.26 Bn | - |
| 2 | Chemed | 18.08 Bn | 18.07 Bn | 215.76 Mn | 142.66 Mn |
| 3 | Tenet Healthcare | 16.59 Bn | 15.76 Bn | 4.41 Bn | - |
| 4 | Davita | 15.37 Bn | 16.23 Bn | 1.07 Bn | - |
| 5 | Encompass Health | 10.07 Bn | 10.70 Bn | 1.34 Bn | - |
| 6 | Ensign | 9.52 Bn | 8.93 Bn | 293.37 Mn | 86.28 Mn |
| 7 | Universal Health Services | 9.19 Bn | 9.15 Bn | 3.21 Bn | - |
| 8 | Pacs | 6.96 Bn | 6.72 Bn | 345.96 Mn | - |
| 9 | Ww International | 6.14 Bn | 5.98 Bn | -149.29 Mn | - |
| 10 | Oncology Institute | 560.93 Mn | 530.65 Mn | 139.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 6.30 Mn |
| Jun 30, 2021 | 6.30 Mn |
| Mar 31, 2021 | 6.30 Mn |
| Dec 31, 2020 | 6.30 Mn |
| Sep 30, 2020 | 6.30 Mn |
| Jun 30, 2020 | 6.30 Mn |
| Mar 13, 2020 | 6.30 Mn |